SHIFT Newsroom · UK
IXCHIQ: UK authorisation withdrawn after safety review
Updated 24 October 2026: the UK authorisation withdrawal announced on 20 October supersedes the older restrictions covered by this archive.
On 20 October 2026, the MHRA announced the withdrawal of IXCHIQ’s UK marketing authorisation following a further safety review. The regulator concluded that its benefits no longer outweigh its risks for UK travellers. Healthcare professionals must no longer prescribe, supply or administer IXCHIQ. MHRA withdrawal notice
This archive originally covered the restrictions announced on 11 February 2026, including the exclusion of people aged 60 and over and several underlying conditions. Those February eligibility restrictions must not be read as permission to use IXCHIQ now: the later UK authorisation withdrawal supersedes them. Original historical notice
The MHRA says people already vaccinated do not need another vaccination or specific medical treatment because of this decision. Anyone experiencing a suspected side effect should seek medical advice and report it through the Yellow Card scheme. Current MHRA patient advice
This decision concerns IXCHIQ specifically. Travellers should discuss current alternatives and mosquito-bite prevention with a travel-health professional; this article does not assess individual vaccine suitability.
SHIFT’s take
UK authorisation has been withdrawn. The earlier restrictions in this archive must not be used as current eligibility advice.
Known facts
- The MHRA announced the UK authorisation withdrawal on 20 October 2026.
- The older notice records a historical restriction, superseded by subsequent regulatory decisions.